Highest-materiality recent filing
INOVIO reports Q2 2026 net loss of $6.0M; INO-3107 PDUFA on Oct 30, 2026
Net loss of $6.0M ($0.07/share) vs $23.5M ($0.61) in Q2 2025; includes $13.9M non-cash warrant gain.
Inovio prices $20M public offering of common stock and warrants
Offering of 21,052,632 shares and warrants to purchase up to 42,105,264 shares at $1.10 exercise price.
Inovio Q1 net loss $19.7M ($0.28/shr); cash runway into Q1 2027 beyond Oct PDUFA
Net loss $19.7M, flat YoY; diluted EPS ($0.28) vs ($0.51) due to fewer shares.
Inovio prices $17.5M public offering of 12.5M shares and warrants; net proceeds ~$16M
12.5M shares and Series A/B warrants (each exercisable for 1 share at $1.40) priced at $1.40 per unit.
Inovio suspends ATM prospectus; raised $3.2M from 1.3M shares under program
On April 1, 2026, Inovio notified Oppenheimer of suspension and termination of the ATM prospectus from August 13, 2024.
Inovio reports FY 2025 net loss $84.9M; INO-3107 BLA accepted with PDUFA Oct 30, 2026
Q4 2025 net income $3.8M ($0.06 basic EPS) mainly from $21.2M non-cash warrant gain; FY net loss $84.9M ($1.81/share).
BLA accepted for review; FDA classified as standard; no advisory committee planned.
Inovio prices 15.1M share offering at $1.90, net proceeds ~$26.5M
Inovio sold 13.158M shares at $1.90; underwriters exercised option for 1.974M additional shares.
INOVIO completes rolling BLA for INO-3107; Q3 net loss $45.5M, cash runway into Q2 2026
Completed rolling BLA submission for INO-3107 (RRP); priority review requested; potential FDA decision mid-2026.
Inovio Q2 net loss narrows to $23.5M; BLA for INO-3107 on track for 2H25 submission
Net loss $23.5M ($0.61/share) vs $32.2M ($1.19/share) YoY; total operating expenses $23.1M down from $33.3M.
Inovio prices $25M public offering of common stock and warrants
Gross proceeds of $25M from 14,285,715 shares and accompanying Series A/B warrants at $1.75/unit.
Inovio Q1 net loss narrows to $19.7M; BLA submission for INO-3107 on track for mid-2025
Net loss narrowed to $19.7M ($0.51/share) from $30.5M ($1.31) in Q1 2024.
Inovio reports FY2024 net loss $107.3M; on track for INO-3107 BLA submission mid-2025
Net loss $19.4M Q4 ($0.65/share) and $107.3M FY ($3.95/share), narrower than 2023's $135.1M.
Inovio prices $30M public offering of 10M shares and warrants
10M shares at $3.00/share plus warrants to buy 10M shares at $3.76, 5-year term.
Inovio Q3 net loss $25.2M; INO-3107 BLA on track for mid-2025 submission
Net loss of $25.2M ($0.89/share) vs $33.9M loss in Q3 2023; R&D expense $18.7M, G&A $8.6M.
INOVIO enters $60M at-the-market equity distribution agreement with Oppenheimer
Sales agreement enables INOVIO to sell up to $60M of common stock via Oppenheimer as agent.
Net loss of $32.2M ($1.19/share) vs $35.5M ($1.61/share) in Q2 2023; revenue not disclosed.
Inovio Q1 net loss narrows to $30.5M; BLA for INO-3107 on track for H2 2024
BLA submission for INO-3107 (recurrent respiratory papillomatosis) on track for H2 2024 under accelerated approval pathway.
Inovio priced ~$36M underwritten offering of common stock and pre-funded warrants
Priced 2,536,258 shares at $7.693/share and pre-funded warrants for 2,135,477 shares at $7.692/warrant.
Inovio Pharmaceuticals effects 1-for-12 reverse stock split effective January 24, 2024
Every 12 issued and outstanding shares combined into 1 share; par value unchanged at $0.001.
INOVIO gets FDA breakthrough therapy for INO-3107; BLA on accelerated path without Phase 3 trial
FDA granted Breakthrough Therapy designation for INO-3107 to treat Recurrent Respiratory Papillomatosis (RRP).
Inovio receives 180-day Nasdaq extension for minimum bid; stock transferred to Capital Market
Extension to April 29, 2024 to achieve $1.00 closing bid for 10 consecutive days.
FDA confirmed that completed Phase 1/2 trial data for INO-3107 in RRP can support BLA under accelerated approval; previously planned Phase 3 trial no longer required.
Inovio Q2 net loss $35.5M; stops VGX-3100 cervical program, cuts 30% staff
Net loss of $35.5M ($0.13 per share) on revenue of $226K; cash, equivalents & short-term investments $194.9M.
Reduction in force of 58 employees (~30% of full-time employees) committed on July 31, 2023.
INOVIO Q1 2023 net loss $40.6M; VGX-3100 misses in biomarker population
Net loss $40.6M ($0.16/sh) vs $79.1M ($0.36) in Q1 2022; revenue $115K vs $199K.
Inovio Q4 net loss $54.5M; VGX-3100 Phase 3 trial fails primary endpoint in biomarker group
Net loss of $54.5M ($0.22 per share) for Q4 2022; full year net loss $279.8M ($1.17 per share).
Inovio cuts 11% of workforce, expects $4.3M annual savings; securities class action settled for $44M
Reduced headcount by 24 employees (11% of full-time staff); one-time charge of $1.1M in Q1 2023.
INOVIO Q3 net loss narrows to $0.15/sh; cash runway into Q1 2025
Q3 2022 revenue of $9.2M vs $292K in Q3 2021, driven by DoD contract.
Net loss $108.5M ($0.46 per share) vs $82.1M loss a year ago; revenue $784K (up from $273K).
INOVIO cuts 18% workforce (55 employees) and 86% of contractors to extend cash runway to Q3 2024
Headcount reduced by 55 employees (18% of full-time staff) and 86% of contractor agreements terminated.
Net loss $79.1M ($0.36/share) vs $54.4M ($0.27) in Q1 2021; revenue $199K.
Inovio's COVID-19 vaccine INO-4800 selected for WHO Solidarity Trial Vaccines Phase 3
WHO confirmed Oct 26, 2021 that INO-4800 is one of two vaccines in large international Phase 3 Solidarity Trial.
the Board appointed Dr. Jacqueline Shea, currently the Company’s Chief Operating Officer, to serve as the Company’s President and Chief Executive Officer
J. Joseph Kim, President and Chief Executive Officer of the Company, resigned from those positions and also resigned as a member of the Company’s Board of Directors
Max materiality 0.85 · Median 0.65 · Most common event other_material